As you prepare for 2027, early planning of your Real-World Evidence (RWE) strategy is important so you can meet regulatory expectations, reduce overall timelines, and overcome protocol complexity. 

This virtual conference will focus on key areas that may impact the success of drug development in 2027 and beyond, including: 

• Bringing RWE earlier into clinical development to gain confidence in your decisions 
• Understanding what evidence regulators are more likely to accept
• Exploring how digital twins and AI can help reshape trial design 
• Learning how advanced monitoring technologies and AI-driven analytics in Patient Experience Data can be used for early risk detection

If you are based in JAPAC or interested in the region-specific content, please visit the registration page here.

After these four sessions, you can select from three therapeutic-focused sessions: obesity, oncology, or CNS.

Join the session that is best aligned with your needs (with the opportunity to view the others on demand afterwards): 

• How the shifting, self-funded obesity market is reshaping evidence needs and access
• Strategies for turning fragmented oncology data into connected, credible evidence
• Multi-modal approaches to accelerate CNS development with minimal burden on patients

Register now to learn the practical strategies you need to make 2027 the year your evidence programs work harder and provide value throughout the product lifecycle. 

Virtual Event
This event will be held on our virtual platform.  Information on how to access the conference will be shared once you've registered.